News | November 16, 2022
Cadila recognized for its contribution to leprosy treatment
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
The Group will continue to make proactive investments of its management resources in the life science business
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Subscribe To Our Newsletter & Stay Updated
